<DOC>
	<DOC>NCT01629758</DOC>
	<brief_summary>The purpose of this study is to determine whether the combination of the 2 drugs being investigated (IL-21 and anti-PD-1) is safe, and provide preliminary information on the clinical benefits of two different schedules of the combination.</brief_summary>
	<brief_title>Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms by Site</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com All subjects will have locally advanced or metastatic solid tumors For Part 2 (Cohort Expansion): Tumor types will be restricted to clear cell renal cell carcinoma (ccRCC), nonsmall cell lung cancer (NSCLC), and melanoma At least 1 lesion with measurable disease Only subjects with tumor samples that are PDL1 positive or negative are eligible Uncontrolled central nervous system (CNS) or leptomeningeal metastasis Inadequate liver or kidney function History of autoimmune Disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>